Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Movement Disorders

• Altropane Dose for Imaging Patients With Suspected Parkinson's Disease
• Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia
• Role and Mechanism of Probiotics in Improving Motor Symptoms in Mild to Moderate Parkinson's Disease
• Oral Iron Frequency for Childhood Restless Leg Syndrome/Periodic Limb Movement Disorder
• Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
• Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study
• Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease
• Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia
• Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia
• Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease
• Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
• Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia
• Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia
• Heart Rate Variability in Response to Metformin Challenge
• Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia
• Addressing Involuntary Movements in Tardive Dyskinesia
• A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
• Reducing Involuntary Movements in Participants With Tardive Dyskinesia
• Aim to Reduce Movements in Tardive Dyskinesia
• Validation of DaTscan for Detection of Parkinson Disease Related Disorders
• A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia
• Dysport for the Treatment of OMD
• Pyridoxal Kinase Activity in Tardive Dyskinesia
• NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia
• NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
• A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders
• Xenazine in Late Dyskinetic Syndrome With Neuroleptics
• Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
• Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
• NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
• Melatonin Treatment for Tardive Dyskinesia in Schizophrenia
• Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
• Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia
• Study of Blood Lactate Levels in Patients Treated With Antipsychotics
• Tardive Dyskinesia and Cognitive Function
• Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia
• Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia
• Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145)
• Extract of Ginkgo Biloba and Tardive Dyskinesia
• Compassionate Use of Tetrabenazine in the Treatment of Abnormal Movements
• Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia
• Intravenous Immunoglobulins as Effective Treatment in Sydenham's Chorea
• Changes of the Neuronal Activity in the Subthalamic Nucleus Under Remifentanil Sedation During Stereotactic Electrode Implantation
• Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)
• A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential Tremor
• The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial
• Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1)
• Dyskinesia in Parkinson's Disease (Study P04501)
• Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia
• Sarizotan in the Treatment of Neuroleptic-induced Tardive Dyskinesia
• Levetiracetam Treatment of Tardive Dyskinesia
• Movement Disorders Caused by Antipsychotic Drugs in Older Patients
• A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients
• Piracetam for Treatment Tardive Dyskinesia
• Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia
• Treatment of Tardive Dyskinesia With Galantamine
• Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
• Effects of Talampanel on Patients With Advanced Parkinson's Disease
• Treatment of Parkinson's Disease With Eliprodil